MAYINGLONG PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.42 CNY | +1.56% |
|
+2.01% | +13.40% |
| Sales 2022 | 3.53B 488M 39.04B | Sales 2023 | 3.14B 433M 34.67B | Capitalization | 10.42B 1.44B 115B |
|---|---|---|---|---|---|
| Net income 2022 | 479M 66.11M 5.29B | Net income 2023 | 443M 61.14M 4.9B | EV / Sales 2022 | 2 x |
| Net cash position 2022 | 2.67B 368M 29.49B | Net cash position 2023 | 2.78B 384M 30.72B | EV / Sales 2023 | 2.44 x |
| P/E ratio 2022 |
20.4
x | P/E ratio 2023 |
23.5
x | Employees | 2,882 |
| Yield 2022 |
1.55% | Yield 2023 |
1.65% | Free-Float | 62.67% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.56% | ||
| 1 week | +2.01% | ||
| Current month | +23.51% | ||
| 1 month | +23.62% | ||
| 3 months | +22.30% | ||
| 6 months | +21.60% | ||
| Current year | +13.40% |
1 week
26.64
28.40
1 month
21.9429.10
Current year
20.2029.10
1 year
20.2032.20
3 years
17.9933.54
5 years
14.2433.54
10 years
11.5440.40
| Managers | Title | Age | Since |
|---|---|---|---|
You Zhang Xia
CEO | Chief Executive Officer | 46 | - |
Bing Wang
DFI | Director of Finance/CFO | 42 | 27/05/19 |
Li De Wang
CHM | Chairman | 59 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
You Zhang Xia
CEO | Chief Executive Officer | 46 | - |
Li De Wang
CHM | Chairman | 59 | - |
Qi Long Huang
BRD | Director/Board Member | 60 | 12/06/23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 27.42 | +1.56% | 8,094,780 |
| 25/04/24 | 27 | -0.18% | 5,619,420 |
| 24/04/24 | 27.05 | -1.21% | 9,339,993 |
| 23/04/24 | 27.38 | -2.80% | 8,288,164 |
| 22/04/24 | 28.17 | +4.80% | 17,828,820 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
Mayinglong Pharmaceutical Group Co., Ltd. is a China-based company, principally engaged in pharmaceutical production, retailing and wholesaling businesses. The Company's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The Company also provides specialty drugs. The Company is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The Company distributes its products mainly in domestic markets.
Sector
Pharmaceuticals
Calendar
25/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +13.40% | 1.63B | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- 600993 Stock
